Sam Brusco, Associate Editor11.01.22
Radiaction Medical, a company that develops technology for radiation protection during interventional procedures, has gained an additional U.S. Food and Drug Administration (FDA) 510(k) clearance for its Radiation Shielding System to enable compatibility with the Siemens Artis family of fluoroscopy C-Arm machines.
The Radiaction Shield System is a head-to-toe shielding device that blocks radiation scatter at the source. It was previously cleared with Toshiba’s Infinix-I systems.
Clinical studies showed the Shield System can reduce radiation scatter to the entire interventional lab by over 90%, with even higher reductions to the heads and upper bodies of the treating physicians.
“The reactions to our Shield System technology and capabilities have been extremely encouraging. Awareness has been growing about the negative implications of staff radiation exposure in interventional labs, but until now, there was no meaningful, comprehensive way to address the problem,” Jonathan Yifat, Radiaction’s CEO told the press. “We are now in a historic position and uniquely poised to drive a truly novel, integrated, and automated solution to market, and directly into the hands of the dedicated healthcare providers at all levels delivering top-tier patient care.”
The company is expanding its U.S. footprint, recently opening its U.S. Headquarters and Training Center in Fort Lauderdale, Fla. The demonstration, training, and visitation center will host and educate physicians and hospital staff.
The Radiaction Shield System is a head-to-toe shielding device that blocks radiation scatter at the source. It was previously cleared with Toshiba’s Infinix-I systems.
Clinical studies showed the Shield System can reduce radiation scatter to the entire interventional lab by over 90%, with even higher reductions to the heads and upper bodies of the treating physicians.
“The reactions to our Shield System technology and capabilities have been extremely encouraging. Awareness has been growing about the negative implications of staff radiation exposure in interventional labs, but until now, there was no meaningful, comprehensive way to address the problem,” Jonathan Yifat, Radiaction’s CEO told the press. “We are now in a historic position and uniquely poised to drive a truly novel, integrated, and automated solution to market, and directly into the hands of the dedicated healthcare providers at all levels delivering top-tier patient care.”
The company is expanding its U.S. footprint, recently opening its U.S. Headquarters and Training Center in Fort Lauderdale, Fla. The demonstration, training, and visitation center will host and educate physicians and hospital staff.